291 related articles for article (PubMed ID: 31242272)
1. A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III.
Hu D; Zhu Z; Li S; Deng Y; Wu Y; Zhang N; Puri V; Wang C; Zou P; Lei C; Tian X; Wang Y; Zhao Q; Li W; Prabakaran P; Feng Y; Cardosa J; Qin C; Zhou X; Dimitrov DS; Ying T
PLoS Pathog; 2019 Jun; 15(6):e1007836. PubMed ID: 31242272
[TBL] [Abstract][Full Text] [Related]
2. Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine.
Tsai WY; Chen HL; Tsai JJ; Dejnirattisai W; Jumnainsong A; Mongkolsapaya J; Screaton G; Crowe JE; Wang WK
J Virol; 2018 Dec; 92(23):. PubMed ID: 30185598
[TBL] [Abstract][Full Text] [Related]
3. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein.
Smith SA; de Alwis AR; Kose N; Harris E; Ibarra KD; Kahle KM; Pfaff JM; Xiang X; Doranz BJ; de Silva AM; Austin SK; Sukupolvi-Petty S; Diamond MS; Crowe JE
mBio; 2013 Nov; 4(6):e00873-13. PubMed ID: 24255124
[TBL] [Abstract][Full Text] [Related]
4. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes.
Sukupolvi-Petty S; Austin SK; Purtha WE; Oliphant T; Nybakken GE; Schlesinger JJ; Roehrig JT; Gromowski GD; Barrett AD; Fremont DH; Diamond MS
J Virol; 2007 Dec; 81(23):12816-26. PubMed ID: 17881453
[TBL] [Abstract][Full Text] [Related]
5. Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.
Frei JC; Wirchnianski AS; Govero J; Vergnolle O; Dowd KA; Pierson TC; Kielian M; Girvin ME; Diamond MS; Lai JR
J Virol; 2018 Sep; 92(18):. PubMed ID: 29976679
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel infection-enhancing epitope on dengue prM using a dengue cross-reacting monoclonal antibody.
Luo YY; Feng JJ; Zhou JM; Yu ZZ; Fang DY; Yan HJ; Zeng GC; Jiang LF
BMC Microbiol; 2013 Aug; 13():194. PubMed ID: 23987307
[TBL] [Abstract][Full Text] [Related]
7. Genotype-specific neutralization and protection by antibodies against dengue virus type 3.
Brien JD; Austin SK; Sukupolvi-Petty S; O'Brien KM; Johnson S; Fremont DH; Diamond MS
J Virol; 2010 Oct; 84(20):10630-43. PubMed ID: 20702644
[TBL] [Abstract][Full Text] [Related]
8. Dengue and Zika Virus Domain III-Flagellin Fusion and Glycan-Masking E Antigen for Prime-Boost Immunization.
Lin HH; Yang SP; Tsai MJ; Lin GC; Wu HC; Wu SC
Theranostics; 2019; 9(16):4811-4826. PubMed ID: 31367259
[TBL] [Abstract][Full Text] [Related]
9. Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection.
Sukupolvi-Petty S; Brien JD; Austin SK; Shrestha B; Swayne S; Kahle K; Doranz BJ; Johnson S; Pierson TC; Fremont DH; Diamond MS
J Virol; 2013 Aug; 87(16):8826-42. PubMed ID: 23785205
[TBL] [Abstract][Full Text] [Related]
10. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity.
Beltramello M; Williams KL; Simmons CP; Macagno A; Simonelli L; Quyen NT; Sukupolvi-Petty S; Navarro-Sanchez E; Young PR; de Silva AM; Rey FA; Varani L; Whitehead SS; Diamond MS; Harris E; Lanzavecchia A; Sallusto F
Cell Host Microbe; 2010 Sep; 8(3):271-83. PubMed ID: 20833378
[TBL] [Abstract][Full Text] [Related]
11. High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection.
Tsai WY; Lai CY; Wu YC; Lin HE; Edwards C; Jumnainsong A; Kliks S; Halstead S; Mongkolsapaya J; Screaton GR; Wang WK
J Virol; 2013 Dec; 87(23):12562-75. PubMed ID: 24027331
[TBL] [Abstract][Full Text] [Related]
12. Generation and characterization of a monoclonal antibody that cross-reacts with the envelope protein from the four dengue virus serotypes.
León-Juárez M; García-Cordero J; Santos-Argumedo L; Romero-Ramírez H; García-Machorro J; Bustos-Arriaga J; Gutiérrez-Castañeda B; Sepúlveda NV; Mellado-Sánchez G; Cedillo-Barrón L
APMIS; 2013 Sep; 121(9):848-58. PubMed ID: 23331315
[TBL] [Abstract][Full Text] [Related]
13. Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: implications for dengue vaccine design.
Li XQ; Qiu LW; Chen Y; Wen K; Cai JP; Chen J; Pan YX; Li J; Hu DM; Huang YF; Liu LD; Ding XX; Guo YH; Che XY
J Gen Virol; 2013 Oct; 94(Pt 10):2191-2201. PubMed ID: 23851440
[TBL] [Abstract][Full Text] [Related]
14. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.
Ramasamy V; Arora U; Shukla R; Poddar A; Shanmugam RK; White LJ; Mattocks MM; Raut R; Perween A; Tyagi P; de Silva AM; Bhaumik SK; Kaja MK; Villinger F; Ahmed R; Johnston RE; Swaminathan S; Khanna N
PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006191. PubMed ID: 29309412
[TBL] [Abstract][Full Text] [Related]
15. Structural and Functional Characterization of a Cross-Reactive Dengue Virus Neutralizing Antibody that Recognizes a Cryptic Epitope.
Li J; Watterson D; Chang CW; Che XY; Li XQ; Ericsson DJ; Qiu LW; Cai JP; Chen J; Fry SR; Cheung STM; Cooper MA; Young PR; Kobe B
Structure; 2018 Jan; 26(1):51-59.e4. PubMed ID: 29249606
[TBL] [Abstract][Full Text] [Related]
16. Generation of Monoclonal Antibodies against Dengue Virus Type 4 and Identification of Enhancing Epitopes on Envelope Protein.
Tang CT; Liao MY; Chiu CY; Shen WF; Chiu CY; Cheng PC; Chang GJ; Wu HC
PLoS One; 2015; 10(8):e0136328. PubMed ID: 26309127
[TBL] [Abstract][Full Text] [Related]
17. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.
Poddar A; Ramasamy V; Shukla R; Rajpoot RK; Arora U; Jain SK; Swaminathan S; Khanna N
BMC Biotechnol; 2016 Jun; 16(1):50. PubMed ID: 27301568
[TBL] [Abstract][Full Text] [Related]
18. Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope.
Metz SW; Thomas A; White L; Stoops M; Corten M; Hannemann H; de Silva AM
Virol J; 2018 Apr; 15(1):60. PubMed ID: 29609659
[TBL] [Abstract][Full Text] [Related]
19. Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein.
Budigi Y; Ong EZ; Robinson LN; Ong LC; Rowley KJ; Winnett A; Tan HC; Hobbie S; Shriver Z; Babcock GJ; Alonso S; Ooi EE
PLoS Negl Trop Dis; 2018 Feb; 12(2):e0006209. PubMed ID: 29425203
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive mapping of functional epitopes on dengue virus glycoprotein E DIII for binding to broadly neutralizing antibodies 4E11 and 4E5A by phage display.
Frei JC; Kielian M; Lai JR
Virology; 2015 Nov; 485():371-82. PubMed ID: 26339794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]